On July 20, 2026, H.C. Wainwright analyst Raghuram Selvaraju maintained a Neutral rating for Aardvark Therapeutics Inc. and set a price target of $6.00 per share, indicating a slight upside from its $5.86 closing price. This follows a full FDA clinical hold on its lead product, ARD-101, affecting ongoing trials for treating Prader-Willi Syndrome (PWS). Aardvark plans to unblind existing clinical trial data to evaluate efficacy and safety, as discussions with the FDA continue. Financially, the company reported a net loss of $21.6 million in Q1 2026 and has sufficient cash to fund operations through mid-2027. The report highlighted significant risks, including the potential for prolonged development timelines and challenges in securing regulatory approvals.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.streetwisereports.com/article/2026/07/24/us-listed-rare-disease-biotech-hit-with-full-clinical-hold-data-unblinding-ahead.html
